4. Cure, Voice Preservation, Cost
• 5 yr LC
• T1 N0 glottic cancer – 85 – 94%
• T2 N0 glottis cancer – 70 – 80%
• Ultimate LC ranges from 90-95%
• Voice preservation similar between laser and
RT, poorer for open partial laryngectomy
• Influenced by Higher Dose per fraction and Lesser OTT
• Higher cost of open partial laryngectomy
• Transoral laser excision – major complications 0% for T1, 13% for T2
Cancer. 2004 May 1;100(9):1786-92.
Management of T1-T2 glottic carcinomas.
Mendenhall WM1, Werning JW, Hinerman RW, Amdur RJ, Villaret DB.
Author information
Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida 32610-0385, USA. mendewil@shands.ufl.edu
7. Voice quality after TLM and RT
Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):255-60. doi: 10.1016/j.ijrobp.2014.06.032.
Voice quality after treatment of early vocal cord cancer: a randomized trial comparing laser surgery with radiation therapy.
Aaltonen LM1, Rautiainen N2, Sellman J2, Saarilahti K3, Mäkitie A4, Rihkanen H4, Laranne J5, Kleemola L5, Wigren T6, Sala E7, Lindholm P8, Grenman R7, Joensuu H3.
Author information
1
Department of Otorhinolaryngology-Head and Neck Surgery, Helsinki University Central Hospital, and University of Helsinki, Helsinki, Finland. Electronic address: leena-maija.aaltonen@hus.fi.
8. Voice quality after TLM and RT
World J Oncol. 2018 Apr; 9(2): 39–45.
Published online 2018 May 1. doi: 10.14740/wjon1105w
PMCID: PMC5942206
PMID: 29760831
Current Status of Organ Preservation in Carcinoma Larynx
Tapesh Bhattacharyyaa and Cessal Thommachan Kainickalb,c
9. Early supraglottis (T1, T2 N0)
• Primary difference from early glottis cancer is rate of LN metastasis –
10-50% (average 33%)
• Surgical options –
• Open supraglottic laryngectomy
• TLM/TORS
• SCPL-CHEP
• RT (Preferred)
10. Locally advanced laryngeal cancer
(Stage III and IV)
• 25 yrs ago – Total laryngectomy plus conventional PORT
• 1991 – Induction chemotherapy (VA trial)
• 2003 – CTRT (Forastiere et al; RTOG 9111)
• 2013 – Update of RTOG 9111
• Standard of care – CTRT
11. Locally advanced laryngeal cancer
World J Oncol. 2018 Apr; 9(2): 39–45.
Published online 2018 May 1. doi: 10.14740/wjon1105w
PMCID: PMC5942206
PMID: 29760831
Current Status of Organ Preservation in Carcinoma Larynx
Tapesh Bhattacharyyaa and Cessal Thommachan Kainickalb,c
12. Induction chemotherapy in larynx preservation
• GORTEC – Adding docetaxel improves overall response
• TAX 324/323 – TPF improves survival compared to PF. The subset
analysis of laryngeohypopharyngeal cancer patients – significant
improvement of laryngectomy free survival.
• DeCIDE
• PARADIGM
• Budach et al metaanalysis (2016)
No OS/PFS benefit of NACT fb CTRT versus CTRT alone
13. Biological therapy in Organ Preservation
JAMA Otolaryngol Head Neck Surg. 2016 Sep 1;142(9):842-9. doi: 10.1001/jamaoto.2016.1228.
Cetuximab and Radiotherapy in Laryngeal Preservation for Cancers of the Larynx and Hypopharynx: A Secondary Analysis of a Randomized Clinical Trial.
Bonner J1, Giralt J2, Harari P3, Spencer S1, Schulten J4, Hossain A5, Chang SC6, Chin S5, Baselga J7.
Author information
1
Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham.
• The rates of laryngeal preservation at 2 years were 87.9% for CRT vs
85.7% for radiotherapy alone, with an HR of 0.57 (95% CI, 0.23-1.42;
P = .22).
• The HR for laryngectomy-free survival comparing CRT vs radiotherapy
alone was 0.78 (95% CI, 0.54-1.11; P = .17). This study was not
powered to assess organ preservation.
14. Outcome of salvage TL following organ
preservation therapy
Arch Otolaryngol Head Neck Surg. 2003 Jan;129(1):44-9.
Outcome of salvage total laryngectomy following organ preservation therapy: the Radiation Therapy Oncology Group trial 91-11.
Weber RS1, Berkey BA, Forastiere A, Cooper J, Maor M, Goepfert H, Morrison W, Glisson B, Trotti A, Ridge JA, Chao KS, Peters G, Lee DJ, Leaf A, Ensley J.
Author information
1
Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania Medical Center, 3400 Spruce St, 5 Ravdin, Philadelphia, PA 19104, USA. randal.weber@uphs.upenn.edu
• Incidence of major and minor complications ranged from 52 – 59%
• LRC following salvage laryngectomy was 74% for arm 1 and 2 (NACT
fb RT; CTRT); and 90% for arm 3 (RT alone)
• At 24 months the OS was 69%, 71% and 76% respectively (p>0.73)
• Acceptable morbidity
• Survival post salvage TL not influenced by initial treatment
• Primary treatment options: ■ Endoscopic resection (laser/surgery) (see Table 42.3 ), or ■ Radical RT • Surgery: ■ For T1 disease without anterior commissure involvement: º Endoscopic resection; generally laser excision ■ Role of conservative open surgery is diminished with advent of laser; may be used in selected cases • Radiotherapy: ■ For T1–2 disease: º Small fi eld including whole glottis with superior–inferior 2‐cm margins º Altered fractionation schedules, especially in T2 diseases ■ Commonly used RT schedules: º 66–70 Gy in 33–35 fractions over 5.5–6 weeks; 2 Gy/fraction, six fractions per week º RTOG 9512 protocol: 79.2 Gy in 66 fractions over 6.5 weeks; 1.2 Gy/fraction, b.i.d., ten fractions per week
Inclusion criteria for the use of micro-endoscopic laser treatment was: good exposure of the glottic region and the tumour staged Tis or T1 without deep involvement of the anterior commissure, Morgagni’s ventricle, the supraglottic or subglottic region or impairment of vocal cord mobility and posterior extension of the lesion as far as the vocal process. Exclusion criteria: patients with glottic carcinoma which had extended completely to the floor of the ventricle. Endoscopic resection has progressed with the advances made in technology; the developments include modification of rigid endoscopes for improved access, digitally-enhanced telescopic visualization, powered instrumentation, and microspot CO2 laser (Laser Opmilas CO2 50, Zeiss, Germany) set in the superpulse mode (1 to 3 W, 270 µm spot size). The main contraindications to laser cordectomy are:
lesions with deep involvement of the anterior commissure that are in close proximity to the underlying cartilage;
impaired arytenoid mobility: these tumours may invade the cricoarytenoid joint, the posterior cricoarytenoid muscle, or the posterior portion of the cricoid cartilage.